Multimodal Ocular Diagnosis-Guided Precision Acupuncture and Lifestyle Intervention for PCOS
2 september 2026 bijgewerkt door: Peking University Third Hospital
MulticenterClinical Study of Intelligent and Precise Acupuncture and Lifestyle Interventions for Polycystic Ovary Syndrome Guided by Multimodal With Ocular Diagnosis
This study is designed as a prospective, multicenter, parallel-group randomized controlled trial to evaluate the effectiveness of a "precision acupuncture + personalized lifestyle" intervention, guided by dynamic multimodal risk monitoring based on the four diagnostic methods of Traditional Chinese Medicine (TCM), in improving insulin resistance in patients with polycystic ovary syndrome (PCOS).
Compared with "conventional acupuncture + standard lifestyle intervention," the study will primarily assess changes in the homeostatic model assessment of insulin resistance (HOMA-IR) after 12 weeks of treatment.
The safety of the intervention, improvements in endocrine and metabolic profiles, menstrual and ovulatory outcomes, psychological status, quality of life, and health-economic outcomes will also be evaluated.
The study aims to provide evidence for establishing an intelligent and individualized clinical management model for PCOS.
Studie Overzicht
Toestand
Werving
Conditie
Studietype
Ingrijpend
Inschrijving (Geschat)
210
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Haolin Zhang, PhD
- Telefoonnummer: +86 15611963539
- E-mail: zoe@bjmu.edu.cn
Studie Locaties
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100191
- Werving
- Peking University Third Hospital
-
Contact:
- Haolin Zhang, PhD
- Telefoonnummer: +86-10-82264627
- E-mail: zoe@bjmu.edu.cn
-
Beijing, Beijing Municipality, China, 100080
- Nog niet aan het werven
- Beijing Haidian Hospital
-
Contact:
- Haolin Zhang, PhD
- Telefoonnummer: +86-10-82264627
- E-mail: zoe@bjmu.edu.cn
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Aged18-40 years, inclusive.
- Body mass index (BMI) of 25-40 kg/m², inclusive.
- Meeting the 2003 Rotterdam diagnostic criteria for polycystic ovary syndrome (PCOS), defined by the presence of at least two of the following three criteria: Oligo-ovulation or anovulation; Clinical and/or biochemical signs of hyperandrogenism; Polycystic ovarian morphology on ultrasonography.
- Willing to participate voluntarily in the study, able to understand the study procedures, and able to provide written informed consent.
Exclusion Criteria:
- Presence of hyperandrogenemia due to other causes, such as hyperprolactinemia, thyroid disorders, congenital adrenal hyperplasia, or exogenous androgen use.
- Presence of renal disease (creatinine clearance <60 mL/min), hepatic impairment, autoimmune disease, or malignancy.
- Type 1 diabetes mellitus or glycated hemoglobin (HbA1c) >53 mmol/mol (7%). - Use, within the past 3 months, of medications that may affect study assessments, including glucocorticoids, insulin, glucose-lowering agents such as acarbose, antidepressants, hormonal contraceptives, ovulation-inducing agents, or other relevant medications.
- Blood pressure >160/100 mmHg.
- Currently pregnant or breastfeeding, pregnancy within the past 6 months, or planning to become pregnant during the study period.
- Having received continuous acupuncture treatment for at least 2 months prior to study treatment.
- Daily smoking or alcohol consumption.
- Presence of language barriers, psychiatric disorders, or other conditions that may impair the participant's ability to understand the study, comply with the intervention, or complete follow-up assessments.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Precision Acupuncture Plus Personalized Lifestyle Intervention
Participants receive model-guided precision acupuncture, with treatment frequency determined by insulin resistance risk and reassessed every 4 weeks, together with a personalized lifestyle intervention based on multimodal data and individualized glucose-response prediction.
The treatment period is 12 weeks.
|
Acupuncture treatment is guided by a multimodal risk-stratification model using clinical and noninvasive indicators.
Participants receive one of two standardized alternating acupuncture prescriptions with manual and 2-Hz electroacupuncture for 30 minutes.
Treatment frequency is adjusted according to insulin resistance risk: three sessions per week for high risk, two sessions per week for moderate risk, and one session per week for low risk.
Risk is reassessed every 4 weeks during the 12-week treatment period.
Participants receive personalized dietary and lifestyle guidance generated from multimodal data, including dietary images, continuous glucose monitoring data, traditional Chinese medicine constitution, body mass index, body fat percentage, blood pressure, and heart rate.
Foods are dynamically classified as green, orange, or red according to predicted individual glucose responses, and recommendations are adjusted throughout the 12-week intervention.
|
|
Actieve vergelijker: Conventional Acupuncture Plus Lifestyle Intervention
Participants receive conventional acupuncture together with standard lifestyle management, including exercise and nutritional guidance delivered and monitored through the PCOS health management system.
The treatment period is 12 weeks.
|
Participants receive conventional acupuncture according to a standardized treatment protocol, administered three times per week by qualified acupuncture physicians.
Participants receive standard exercise and nutritional guidance through the PCOS health management system.
Exercise is guided and monitored using step-count data, while dietary prescriptions and remote health guidance are delivered through a mobile application and computer-based platform.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
HOMA-IR level after 12 weeks of treatment
Tijdsspanne: End of treatment (Week 12)
|
Fasting venous blood samples will be collected to measure fasting plasma glucose and fasting insulin.
HOMA-IR will be calculated using the following formula: HOMA-IR = fasting plasma glucose (mmol/L) × fasting insulin (μIU/mL) / 22.5.
|
End of treatment (Week 12)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
HOMA-IR level
Tijdsspanne: Baseline (Week 0) and end of follow-up (Week 24)
|
Fasting venous blood samples will be collected to measure fasting plasma glucose and fasting insulin.
HOMA-IR will be calculated using the following formula: HOMA-IR = fasting plasma glucose (mmol/L) × fasting insulin (μIU/mL) / 22.5.
|
Baseline (Week 0) and end of follow-up (Week 24)
|
|
Area under the insulin concentration-time curve during the oral glucose tolerance test
Tijdsspanne: Baseline (0 week), end of treatment (12 week) and end of follow-up (24week).
|
The area under the insulin concentration-time curve (insulin AUC) will be calculated from insulin concentrations measured during the oral glucose tolerance test (OGTT).
A single insulin AUC value will be reported for each assessment.
|
Baseline (0 week), end of treatment (12 week) and end of follow-up (24week).
|
|
Glycated hemoglobin level
Tijdsspanne: Baseline (0 week), end of treatment (12 week) and end of follow-up (24week).
|
Glycated hemoglobin (HbA1c) will be measured using the study site's routine clinical laboratory method.
|
Baseline (0 week), end of treatment (12 week) and end of follow-up (24week).
|
|
Serum anti-Müllerian hormone concentration
Tijdsspanne: Baseline (Week 0), Week 12, and Week 24
|
Serum anti-Müllerian hormone (AMH) concentration will be measured using the study site's routine clinical laboratory method.
|
Baseline (Week 0), Week 12, and Week 24
|
|
Serum total cholesterol concentration
Tijdsspanne: Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
Serum total cholesterol (TC) concentration will be measured using the study site's routine clinical laboratory method.
|
Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
|
Serum triglyceride concentration
Tijdsspanne: Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
Serum triglyceride (TG) concentration will be measured using the study site's routine clinical laboratory method.
|
Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
|
Serum high-density lipoprotein cholesterol concentration
Tijdsspanne: Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
Serum high-density lipoprotein cholesterol (HDL-C) concentration will be measured using the study site's routine clinical laboratory method.
|
Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
|
Serum low-density lipoprotein cholesterol concentration
Tijdsspanne: Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
Serum low-density lipoprotein cholesterol (LDL-C) concentration will be measured using the study site's routine clinical laboratory method.
|
Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
|
Number of menstrual bleeding episodes
Tijdsspanne: During treatment (Weeks 1-12) and during follow-up (Weeks 13-24)
|
articipants will record menstrual bleeding using menstrual cycle diaries.
The number of menstrual bleeding episodes will be summarized separately during the 12-week treatment period and the 12-week follow-up period.
|
During treatment (Weeks 1-12) and during follow-up (Weeks 13-24)
|
|
Number of ovulations
Tijdsspanne: During treatment (Weeks 1-12) and during follow-up (Weeks 13-24)
|
Ovulatory status will be assessed using menstrual cycle records.
When clinically necessary, gynecologic ultrasonography will be used to assess follicular development and endometrial changes.
The number of ovulations will be summarized separately during the treatment and follow-up periods.
|
During treatment (Weeks 1-12) and during follow-up (Weeks 13-24)
|
|
Body weight
Tijdsspanne: Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
Body weight will be measured in kilograms at each assessment.
|
Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
|
Body mass index
Tijdsspanne: Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
Body mass index (BMI) will be calculated as body weight in kilograms divided by height in meters squared (kg/m²).
|
Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
|
Waist circumference
Tijdsspanne: Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
Waist circumference will be measured in centimeters using the standardized study measurement procedure.
|
Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
|
Waist-to-hip ratio
Tijdsspanne: Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
Waist-to-hip ratio will be calculated as waist circumference divided by hip circumference.
A single dimensionless ratio will be reported for each assessment.
|
Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
|
Modified Ferriman-Gallwey hirsutism score
Tijdsspanne: Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
Hirsutism will be assessed using the modified Ferriman-Gallwey score.
Terminal hair growth in nine androgen-sensitive body areas is scored from 0 to 4, producing a total score ranging from 0 to 36.
Higher scores indicate more severe hirsutism.
|
Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
|
Polycystic Ovary Syndrome Questionnaire total score
Tijdsspanne: Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
Health-related quality of life will be assessed using the 30-item Polycystic Ovary Syndrome Questionnaire (PCOSQ) described in the protocol.
Each item is scored from 1 to 7. The total score is calculated as the sum of all item scores and ranges from 30 to 210, with higher scores indicating better health-related quality of life.
|
Baseline (Week 0), end of treatment (Week 12), and end of follow-up (Week 24)
|
|
Number of participants with adverse events
Tijdsspanne: From the first study intervention through the end of follow-up (Week 24)
|
Adverse events will be recorded at each study visit and classified as mild, moderate, or severe.
Events of interest include hypoglycemia, defined as blood glucose below 3.9 mmol/L; acute diabetic complications; and acupuncture-related events such as bleeding, hematoma, fainting, needling-site pain, and elevated blood pressure.
The number and percentage of participants experiencing at least one adverse event will be reported.
|
From the first study intervention through the end of follow-up (Week 24)
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
10 juli 2026
Primaire voltooiing (Geschat)
31 december 2028
Studie voltooiing (Geschat)
31 december 2028
Studieregistratiedata
Eerst ingediend
19 augustus 2026
Eerst ingediend dat voldeed aan de QC-criteria
2 september 2026
Eerst geplaatst (Werkelijk)
9 september 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
9 september 2026
Laatste update ingediend die voldeed aan QC-criteria
2 september 2026
Laatst geverifieerd
1 augustus 2026
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- PKUTH TCM
- 2026-2-40912 (Andere identificatie: Beijing Municipal Health Commission)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Beschrijving IPD-plan
Individual participant data will not be shared.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .